Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
base editing
Biotech
Verve posts clean PCSK9 editor profile, teeing up Lilly decision
One year after axing an asset, the biotech has shown its Lilly-partnered successor can achieve similar LDL-C reductions without raising any red flags.
Nick Paul Taylor
Apr 14, 2025 7:00am
Beam hits hemoglobin goal in first base editing clinical data
Nov 5, 2024 9:00am
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
Apr 2, 2024 7:00am
PKU in mice treated with base and prime editing
Nov 3, 2023 1:08pm
Beam lays off 20% of staff and culls CAR-T work to save cash
Oct 19, 2023 11:00am
Revvity rolls out base editing reagents for preclinical labs
Sep 28, 2023 1:57pm